- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | BIOPHYTIS: Biophytis Will Be In San Franscico During The 2025 JP Morgan Healthcare Conference | 1 | Euronext | ||
| Mo | BIOPHYTIS: Biophytis showcased the OBA program in obesity at the 17th SCWD international congress | 4 | Euronext | ||
| 02.12. | BIOPHYTIS: Biophytis participates in the 17th SCWD Congress and hosts an Obesity Investor Call | 4 | Euronext | ||
| 11.10. | Biophytis GAAP EPS of -€9.48 | 4 | Seeking Alpha | ||
| BIOPHYTIS SA ADR Aktie jetzt für 0€ handeln | |||||
| 30.09. | Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 396 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing... ► Artikel lesen | |
| 30.09. | BIOPHYTIS: Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities | 3 | Euronext | ||
| 30.09. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 22.07. | Biophytis SA - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 22.07. | Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia | 451 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the... ► Artikel lesen | |
| 11.07. | Biophytis SA - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 11.07. | Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity | 310 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 01.07. | Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris | 371 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 26.06. | Delisting of Securities of PHP Ventures Acquisition Corp.; Green Giant Inc.; RMG Acquisition Corp. III; Biophytis SA; OMNIQ Corp.; AIB Acquisition Corporation; Goal Acquisitions Corp.; Applied UV, Inc.; Cue Health Inc. and others | 270 | GlobeNewswire (Europe) | NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, rights, warrants, and units of PHP Ventures Acquisition Corp. PHP Ventures Acquisition... ► Artikel lesen | |
| 20.06. | Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million | 350 | ACCESSWIRE | Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the productAgreement covers commercialization of BIO101... ► Artikel lesen | |
| 20.06. | Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities | 441 | ACCESSWIRE | Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting... ► Artikel lesen | |
| 12.06. | Biophytis Announces the Successful Industrial Transfer of BIO101 Production by its Service Provider Seqens | 335 | ACCESSWIRE | PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 10.06. | Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity | 299 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 07.06. | Biophytis: Combined General Meeting of June 24, 2024 | 203 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 14.05. | Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity | 652 | ACCESSWIRE | PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development... ► Artikel lesen | |
| 06.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.05.2024 | 568 | Xetra Newsboard | Das Instrument DEV US23304Y1001 DBS GROUP ADR/4 SD 1 EQUITY wird ex Kapitalmassnahme gehandelt am 06.05.2024 The instrument DEV US23304Y1001 DBS GROUP ADR/4 SD 1 EQUITY is traded ex capital adjustment... ► Artikel lesen |
Seite:
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CUREVAC | 3,024 | -0,72 % | CureVac Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VALNEVA | 2,214 | +0,73 % | Valneva: Wilde Kursausschläge - Analysten sehen Vervielfachungspotenzial | Die Aktie von Valneva hat sich zuletzt von den 52-Wochen-Tiefs lösen können. Für frischen Rückenwind sorgte eine exklusive Lizenzvereinbarung mit dem weltgrößten Impfstoffproduzenten, dem Serum Institute... ► Artikel lesen | |
| BIOFRONTERA | 2,190 | -1,13 % | PTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2024 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2024
Unternehmensmitteilung für den Kapitalmarkt
Leverkusen (pta/29.11.2024/17:00)... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 1,026 | -2,84 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| AAP IMPLANTATE | 1,330 | -7,64 % | EQS-DD: aap Implantate AG: Merval AG, Bezug von Aktien durch Ausübung von Wandlungsrechten | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
17.12.2024 / 12:31... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,760 | -1,68 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| SANGAMO THERAPEUTICS | 2,501 | +1,63 % | Sangamo: Das Comeback des Jahres - und es wird noch besser | Die Aktie des Biotech-Unternehmens Sangamo lag völlig am Boden, das Management stand mit dem Rücken zur Wand. Doch die Firma hat in der zweiten Jahreshälfte geliefert - und wie. Sangamo konnte mehrere... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,525 | +0,26 % | Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now? | ||
| VIKING THERAPEUTICS | 39,600 | +0,35 % | Unpacking the Latest Options Trading Trends in Viking Therapeutics | ||
| SCORPIUS | 0,322 | +3,44 % | Scorpius Holdings files to sell 29.41 million shares of common stock, warrants | ||
| EDITAS MEDICINE | 1,157 | -0,73 % | Editas Medicine Aktie stürzt auf 52-Wochen-Tief von 1,27 US-Dollar | ||
| SAREPTA THERAPEUTICS | 116,20 | -0,39 % | Sarepta Therapeutics Q3 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Sarepta Therapeutics (SRPT):Earnings: $33.6 million in Q3 vs. -$40.9 million in the same period last year.
EPS: $0.34 in Q3 vs.... ► Artikel lesen | |
| REDHILL BIOPHARMA | 6,700 | +2,29 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| IBIO | 3,515 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended... ► Artikel lesen |
Das Unternehmen BIOPHYTIS SA ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,224 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOPHYTIS SA ADR finden Sie auf Wallstreet Online.
